Liquidia’s (LQDA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Liquidia (NASDAQ:LQDA) in a research note released on Thursday,Benzinga reports. The firm currently has a $29.00 price target on the stock.

Other analysts have also issued reports about the stock. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Lifesci Capital began coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Liquidia in a report on Thursday. BTIG Research lowered their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a report on Monday, August 19th. Finally, Bank of America cut their price target on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.00.

Liquidia Stock Performance

LQDA stock traded down $0.04 during mid-day trading on Thursday, reaching $9.98. 365,846 shares of the stock traded hands, compared to its average volume of 978,632. The stock has a market capitalization of $766.36 million, a PE ratio of -6.15 and a beta of 0.21. Liquidia has a one year low of $6.10 and a one year high of $16.99. The business has a 50-day moving average price of $10.48 and a two-hundred day moving average price of $11.52.

Insider Transactions at Liquidia

In other news, Director Caligan Partners Lp bought 150,000 shares of Liquidia stock in a transaction on Friday, August 30th. The stock was acquired at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the acquisition, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. The trade was a 2.19 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Rajeev Saggar sold 2,526 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the transaction, the insider now owns 204,857 shares in the company, valued at approximately $2,292,349.83. This trade represents a 1.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,551 shares of company stock valued at $236,021 in the last ninety days. 30.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Liquidia

Hedge funds have recently bought and sold shares of the business. Swiss National Bank purchased a new position in Liquidia during the first quarter worth about $1,325,000. Sei Investments Co. purchased a new position in Liquidia in the first quarter worth approximately $531,000. Bleakley Financial Group LLC lifted its holdings in Liquidia by 6.6% during the 1st quarter. Bleakley Financial Group LLC now owns 33,250 shares of the company’s stock worth $490,000 after buying an additional 2,057 shares during the last quarter. Vanguard Group Inc. increased its stake in Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock valued at $42,587,000 after purchasing an additional 43,352 shares during the last quarter. Finally, American International Group Inc. grew its position in shares of Liquidia by 5.2% in the 1st quarter. American International Group Inc. now owns 24,806 shares of the company’s stock valued at $366,000 after buying an additional 1,215 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).